Application Value of Color Ultrasound Combined with Serum gal-3 and sST2 in the Diagnosis of Hypertensive Left Ventricular Hypertrophy with Left Heart Failure
JIA Bei, XIAO Wang-li
Department of Ultrasound,Xianyang Hospital,Yan'an University,Xianyang Shaanxi 712000
Abstract 【Objective】To study the application value of color ultrasound combined with serum galactose agglutinin-3(gal-3) and soluble growth stimulating expression gene 2 protein(sST2) in the diagnosis of hypertensive left ventricular hypertrophy with left heart failure. 【Methods】96 hypertensive left ventricular hypertrophy with left heart failure patients diagnosed in our hospital from January 2018 to December 2021 were included in the study group, and 96 patients without cardiovascular disease who underwent physical examination in our hospital during the same period were included in the control group.Color ultrasound combined with serum gal-3 and sST2 were performed in both groups. Color ultrasound indexes and serum gal-3 and sST2 levels of patients with different cardiac function grades were compared between the two groups and the study group. The color ultrasound indexes and serum gal-3 and sST2 levels of patients with different cardiac function grades in the study group were compared, and the correlation between color ultrasound indexes, serum gal-3 and sST2 levels and cardiac function grades was analyzed by Pearson correlation.【Results】LVESD, LVEDD, LAD, IVST, LVPWT, left ventricular Tei index and serum gal-3 and sST2 levels in the study group were higher than those in the control group, LVFS, LVEF and E/A were lower than those in the control group (P<0.05). In the study group, LVESD, LVEDD, LAD, IVST, LVPWT, left ventricular Tei index and serum gal-3 and sST2 levels of patients with grade Ⅳ cardiac function were higher than those of patients with grade Ⅱ and Ⅲ cardiac function, LVFS, LVEF and E/A were lower than those of patients with grade Ⅱ and Ⅲ cardiac function (P<0.05). LVESD, LVEDD, LAD, IVST, LVPWT, left ventricular Tei index and serum gal-3 and sST2 levels were higher in grade Ⅲ patients than in grade Ⅱ patients, LVFS, LVEF and E/A were lower than in grade Ⅱ patients (P<0.05). Pearson correlation analysis showed that serum gal-3 and sST2 levels of LEFT ventricular Tei index were positively correlated with cardiac function grading, while E/A, LVEF, LVFS were negatively correlated with cardiac function grading (P<0.05). There was no correlation between LVESD, LVEDD, LAD, IVST, LVPWT and cardiac function grading (P>0.05). 【Conclusion】Color ultrasound combined with serum gal-3 and sST2 has high diagnostic value for hypertensive left ventricular hypertrophy with left heart failure, and can be applied to clinical diagnosis of hypertensive left ventricular hypertrophy with left heart failure.
JIA Bei,XIAO Wang-li. Application Value of Color Ultrasound Combined with Serum gal-3 and sST2 in the Diagnosis of Hypertensive Left Ventricular Hypertrophy with Left Heart Failure[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1505-1508.
[1] SLIVNICK J,LAMPERT B C. Hypertension and heart failure[J].Heart Fail Clin,2019,15(4):531-541.
[2] 贺治民,李艳华,王冉冉,等. 心脏彩超在高血压左室肥厚伴左心衰竭诊断中的应用研究[J].实用临床医药杂志,2018,22(24):24-26.
[3] 涂睿. 心脏彩超在高血压左室肥厚伴左心衰竭诊断中的价值研究[J].医药论坛杂志,2021,42(13):136-138.
[4] BLANDA V,BRACALE U M,DI TARANTO M D,et al. Galectin-3 in cardiovascular diseases[J].Int J Mol Sci,2020,21(23):9232.
[5] POURAFKARI L,TAJLIL A,NADER N D. Biomarkers in diagnosing and treatment of acute heart failure[J].Biomark Med,2019,13(14):1235-1249.
[6] 郭继鸿. 临床实用心血管病学[M]. 北京:北京大学医学出版社,2015:183.
[7] SORRENTINO M J. The Evolution from hypertension to heart failure[J].Heart Fail Clin,2019,15(4):447-453.
[8] LE T T,LIM V,IBRAHIM R,et al. The remodelling index risk stratifies patients with hypertensive left ventricular hypertrophy[J].Eur Heart J Cardiovasc Imaging,2021,22(6):670-679.
[9] GARG P,ASSADI H,JONES R,et al. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction[J].Sci Rep,2021,11(1):617.
[10] 石霄杰. 心脏彩超用于诊断高血压左室肥厚伴左心衰竭的价值分析[J].医药论坛杂志,2020,41(2):49-51.
[11] MARTÍNEZ-MARTÍNEZ E,BRUGNOLARO C,IBARROLA J,et al. CT-1 (Cardiotrophin-1)-gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation[J].Hypertension,2019,73(3):602-611.
[12] KOMICI K,GNEMMI I,BENCIVENGA L,et al. Impact of galectin-3 circulating levels on frailty in elderly patients with systolic heart failure[J].J Clin Med,2020,9(7):2229.
[13] CHAIKIJURAJAI T,TANG W H W. Reappraisal of inflammatory biomarkers in heart failure[J].Curr Heart Fail Rep,2020,17(1):9-19.
[14] GHALI R,ALTARA R,LOUCH W E,et al. IL-33 (Interleukin 33)/sST2 axis in hypertension and heart failure[J].Hypertension,2018,72(4):818-828.
[15] AIMO A,JANUZZI J L JR,BAYES-GENIS A,et al. Clinical and prognostic significance of sST2 in heart failure:JACC review topic of the week[J].J Am Coll Cardiol,2019,74(17):2193-2203.
2022, Vol. 39 
